These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38714043)

  • 1. Recent discovery and development of AXL inhibitors as antitumor agents.
    Liu Z; Chen L; Zhang J; Yang J; Xiao X; Shan L; Mao W
    Eur J Med Chem; 2024 Jun; 272():116475. PubMed ID: 38714043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of dual Axl/VEGF-R2 inhibitors as potential anti-angiogenic and anti-metastatic drugs for cancer chemotherapy.
    Goff D; Zhang J; Heckrodt T; Yu J; Ding P; Singh R; Holland S; Li W; Irving M
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3766-3771. PubMed ID: 28711351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation.
    Xu D; Sun D; Wang W; Peng X; Zhan Z; Ji Y; Shen Y; Geng M; Ai J; Duan W
    Eur J Med Chem; 2021 Aug; 220():113497. PubMed ID: 33957388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications.
    Zhu C; Wei Y; Wei X
    Mol Cancer; 2019 Nov; 18(1):153. PubMed ID: 31684958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells.
    Corno C; Gatti L; Lanzi C; Zaffaroni N; Colombo D; Perego P
    Curr Med Chem; 2016; 23(15):1496-512. PubMed ID: 27048336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors.
    Tan L; Zhang Z; Gao D; Luo J; Tu ZC; Li Z; Peng L; Ren X; Ding K
    J Med Chem; 2016 Jul; 59(14):6807-25. PubMed ID: 27379978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of new Axl kinase inhibitors containing 1,3,4-oxadiazole acetamide moiety as novel linker.
    Xu C; Han Y; Xu S; Wang R; Yue M; Tian Y; Li X; Zhao Y; Gong P
    Eur J Med Chem; 2020 Jan; 186():111867. PubMed ID: 31757525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Research Progress of Axl Inhibitors.
    Sun ZG; Liu JH; Zhang JM; Qian Y
    Curr Top Med Chem; 2019; 19(15):1338-1349. PubMed ID: 31218961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Dual MER/AXL Kinase Inhibitors as Bifunctional Small Molecules for Inhibiting Tumor Growth and Enhancing Tumor Immune Microenvironment.
    Li MC; Lai YL; Kuo PH; Reddy JS; Chen CM; Manimala J; Wang PC; Wu MS; Chang CY; Yang CM; Lin CY; Huang YC; Chiu CH; Chang L; Lin WH; Yeh TK; Yen WC; Hsieh HP
    J Med Chem; 2024 Jul; 67(13):10906-10927. PubMed ID: 38913493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of the phenylpyrazolo[3,4-
    Lee HJ; Pham PC; Pei H; Lim B; Hyun SY; Baek B; Kim B; Kim Y; Kim MH; Kang NW; Min HY; Kim DD; Lee J; Lee HY
    Theranostics; 2021; 11(4):1918-1936. PubMed ID: 33408789
    [No Abstract]   [Full Text] [Related]  

  • 11. Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC.
    Konen JM; Rodriguez BL; Padhye A; Ochieng JK; Gibson L; Diao L; Fowlkes NW; Fradette JJ; Peng DH; Cardnell RJ; Kovacs JJ; Wang J; Byers LA; Gibbons DL
    Cancer Res; 2021 Mar; 81(5):1398-1412. PubMed ID: 33402388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accelerating AXL targeting for TNBC therapy.
    Khera L; Lev S
    Int J Biochem Cell Biol; 2021 Oct; 139():106057. PubMed ID: 34403827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axl inhibitors as novel cancer therapeutic agents.
    Shen Y; Chen X; He J; Liao D; Zu X
    Life Sci; 2018 Apr; 198():99-111. PubMed ID: 29496493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer.
    Palisoul ML; Quinn JM; Schepers E; Hagemann IS; Guo L; Reger K; Hagemann AR; McCourt CK; Thaker PH; Powell MA; Mutch DG; Fuh KC
    Mol Cancer Ther; 2017 Dec; 16(12):2881-2891. PubMed ID: 28904132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression.
    von Mässenhausen A; Brägelmann J; Billig H; Thewes B; Queisser A; Vogel W; Kristiansen G; Schröck A; Bootz F; Brossart P; Kirfel J; Perner S
    Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28025482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine derivatives as novel selective Axl inhibitors.
    Inoue S; Yamane Y; Tsukamoto S; Murai N; Azuma H; Nagao S; Nishibata K; Fukushima S; Ichikawa K; Nakagawa T; Hata Sugi N; Ito D; Kato Y; Goto A; Kakiuchi D; Ueno T; Matsui J; Matsushima T
    Bioorg Med Chem Lett; 2021 Sep; 48():128247. PubMed ID: 34271070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of novel aminopyrimidinylisoindolines as AXL kinase inhibitors.
    Choi MJ; Roh EJ; Hur W; Lee SH; Sim T; Oh CH; Lee SH; Kim JS; Yoo KH
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3761-3765. PubMed ID: 30340900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.
    Burbridge MF; Bossard CJ; Saunier C; Fejes I; Bruno A; Léonce S; Ferry G; Da Violante G; Bouzom F; Cattan V; Jacquet-Bescond A; Comoglio PM; Lockhart BP; Boutin JA; Cordi A; Ortuno JC; Pierré A; Hickman JA; Cruzalegui FH; Depil S
    Mol Cancer Ther; 2013 Sep; 12(9):1749-62. PubMed ID: 23804704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AXL kinase as a novel target for cancer therapy.
    Wu X; Liu X; Koul S; Lee CY; Zhang Z; Halmos B
    Oncotarget; 2014 Oct; 5(20):9546-63. PubMed ID: 25337673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of A-910, a Highly Potent and Orally Bioavailable Dual MerTK/Axl-Selective Tyrosine Kinase Inhibitor.
    Yu Y; Jang M; Miyashiro J; Clark RF; Zhu GD; Gong J; Dai Y; Frey RR; Penning TD; Kim H; Lee HK; Kim JK; Ryu KM; Park SJ; Yoon T; Li T; Kurnick MD; Kapecki NJ; Li L; Gorman JV; Montgomery DA; Manaves V; Bromberg KD; Doktor SZ; Thakur A; Wang J; Smith HA; Buchanan FG; Ferguson DC; Torrent M; Jakob CG; Qiu W; Upadhyay AK; Martin RL; Lai A; Michaelides MR
    J Med Chem; 2024 Oct; 67(19):17000-17032. PubMed ID: 39283694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.